Lantheus weighs 7 billion dollar sale to Curium Pharma
Lantheus Holdings is weighing a 7 billion dollar sale after a bid from Curium Pharma. Talks are ongoing but no final decision has been reached by either party.
Xurve View
Insights:
Xurve View
LANTHEUS HOLDINGS INC is considering a $7 billion takeover offer from private-equity backed Curium Pharma. The bid values the radiopharmaceutical firm at a premium to its current $6.15 billion market capitalization. A deal would consolidate the nuclear medicine sector following Lantheus's 54.8% share price gain this year.
